Islatravir/lenacapavir vs Lenacapavir (Yeztugo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Islatravir/lenacapavir
Developed by Gilead Sciences and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Lenacapavir (Yeztugo)
Marketed by Gilead Sciences
NCT04994509 · Phase 3 · active, not recruiting
This is a very large randomized, double-blind trial with active-control arms and a hard primary endpoint, HIV-1 infection. Lenacapavir's HIV incidence was far below the background rate and met the prespecified superiority tests. The primary comparison is against a background rate estimated from screened participants, not directly against the control arms.
Next expected readout: March 2027 · NCT07210125 (registry estimate)
Reported efficacy
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) (Incidence Phase Screening Visit (Day 1)); Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) (Up to 149 weeks): HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). (met)
Result source: NCT04925752
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Islatravir/lenacapavir | Lenacapavir (Yeztugo) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06630286 | —Trial running · NCT04925752 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06630286 | —Trial running · NCT04925752 |
| CD4 count, change (week 48) | —Trial running · NCT06630286 | —Trial running · NCT04925752 |
HIV-1 RNA below 50 copies/mL (week 48)
- Islatravir/lenacapavir
- —Trial running · NCT06630286
- Lenacapavir (Yeztugo)
- —Trial running · NCT04925752
HIV-1 RNA 50 copies/mL or more (week 48)
- Islatravir/lenacapavir
- —Trial running · NCT06630286
- Lenacapavir (Yeztugo)
- —Trial running · NCT04925752
CD4 count, change (week 48)
- Islatravir/lenacapavir
- —Trial running · NCT06630286
- Lenacapavir (Yeztugo)
- —Trial running · NCT04925752
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Islatravir/lenacapavir: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Islatravir/lenacapavir: 0 of 4 rows · Lenacapavir (Yeztugo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lenacapavir (Yeztugo) |
|---|---|
| Dropout rate | 11.5% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more result94.4% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
| Discontinued due to AEs | 0.1% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more result0.2% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
| Serious AEs | 3.8% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more result3.3% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
| Most frequent reported AEs | injection site nodule 66.1% injection site pain 34.2% genitourinary chlamydia infection 16.4% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more resultinjection site nodule 63.4% injection site pain 56.4% injection site erythema 17.3% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lenacapavir (Yeztugo)
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Islatravir/lenacapavir's landscape · Lenacapavir (Yeztugo)'s landscape